PDSI phase 2 measures for CLCs
| PDSI CLC measure | Definition |
| Anticholinergic antidepressant | Anticholinergic antidepressant use in patients who are 75 or older |
| Anticholinergic polypharmacy | Two or more anticholinergic medications in patients who are 75 or older |
| Antihistamine use | Antihistamine use in patients who are 75 or older |
| Antipsychotic use with dementia | Antipsychotic use in patients with dementia, without diagnosis of psychosis, schizophrenia or bipolar disorder |
| Antipsychotic use monitoring | Lack of glucose or A1c in patients who are 75 or older taking antipsychotic medications |
| Benzodiazepine use with dementia | Benzodiazepine use in patients with dementia who are 75 or older |
| Benzodiazepine or sedative use | Benzodiazepine use in patients who are 75 or older |
CLC, Community Living Center; PDSI, Psychotropic Drug Safety Initiative.